---
title: "Livzon Pharmaceutical Vice President Resigns but Remains in Company Role"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300025859.md"
description: "Livzon Pharmaceutical Group announced that Vice President Xu Xiao has resigned from his VP role due to work adjustments but will remain in other company positions. The board confirmed this change does not affect normal operations, noted Xu holds no shares, and emphasized management stability with no disagreements. The stock currently carries a 'Sell' rating with a HK$22.99 price target."
datetime: "2026-09-24T11:44:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300025859.md)
  - [en](https://longbridge.com/en/news/300025859.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300025859.md)
generator: "portal-rs"
---

# Livzon Pharmaceutical Vice President Resigns but Remains in Company Role

Livzon Pharmaceutical Group ( (HK:1513) ) has provided an update.

Livzon Pharmaceutical Group has announced that Mr. Xu Xiao has resigned from his role as vice president due to work adjustments, though he will remain in other positions within the company. The board emphasized that the move will not affect the company’s normal operations, noted that Mr. Xu holds no shares, and expressed appreciation for his diligent service.

The company also reaffirmed the current composition of its board, which includes executive, non-executive, employee representative and independent non-executive directors, underscoring continuity in overall governance. By clarifying that there are no disagreements related to the resignation and no issues requiring shareholder attention, Livzon sought to reassure investors about management stability and ongoing corporate oversight.

The most recent analyst rating on (HK:1513) stock is a Sell  
 with a HK$22.99 price target.  
 To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock,  
 see the HK:1513 Stock Forecast page. 

**More about Livzon Pharmaceutical Group**

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company focused on the research, development, manufacturing and sale of medicines and related healthcare products. The group operates through multiple subsidiaries and is listed in Hong Kong, giving it access to international capital markets and a broad base of institutional and retail investors.

**Average Trading Volume:** 1,206,622

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$24.62B

Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)

## Related News & Research

- [Livzon Pharmaceutical to Buy 0.13% Stake in Xinbeijiang Pharma for RMB 3.85 Million](https://longbridge.com/en/news/305166524.md)
- [Livzon Pharmaceutical Sees Profit and Revenue Drop in Q3 2026](https://longbridge.com/en/news/302849014.md)
- [Tesla’s Cheapest Model Y Gets More Range in the U.S., But Not in Canada](https://longbridge.com/en/news/305577641.md)
- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**